CVS Health is in the early stages of an operational turnaround, with revenue growing to $402B in 2025 and AI-driven efficiency gains in claims processing, but profitability remains depressed (EPS of $1.39 vs. $3.66 in 2024) and leverage elevated. The stock has rallied 80% since May 2024 and now trades at a PE of 40.5x, more than double the peer median, which already discounts a recovery. Hold for clearer evidence that cost initiatives translate into sustained earnings improvement.
Margin pressure
Gross profit margin declined in 2024 and only partially recovered in 2025; operating income of $10.4B remains well below the $13.7B achieved in 2023.
High leverage
Total debt increased to $93.6B in 2025, pushing the debt-to-equity ratio to 1.24x, which raises interest burden and financial risk.
Execution risk
Turnaround efforts, including AI and operational changes, may fail to restore bottom-line growth if cost pressures or competitive dynamics intensify.
Stretched valuation
At 40.5x earnings, the stock is priced for perfection; any earnings miss could trigger a sharp de-rating toward the peer median PE of 19.6x.